Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of QL2107 vs Keytruda in Healthy Male Adults
NCT06173011Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL2107 in solid tumor (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Area Under the Curve from time zero to infinity at 113 days. Started Dec 2023; status: recruiting.
02
Drugs
QL2107
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06173011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173011.